tirzepatide mastery course
Unit 1 of 12 -- free

Introduction to Tirzepatide

How a single peptide targeting two receptors became the most effective approved obesity and diabetes drug

The Drug That Changed the Ceiling

In May 2022, the FDA approved Mounjaro (tirzepatide) for Type 2 diabetes. In November 2023, it gained a second approval as Zepbound for chronic weight management. The molecule behind both brand names is tirzepatide, a first-in-class dual GIP/GLP-1 receptor agonist developed by Eli Lilly.

Before tirzepatide, the best obesity drugs produced roughly 15% mean body-weight loss. Tirzepatide pushed past 20% in the SURMOUNT-1 trial -- a result that closed the gap between pharmacotherapy and bariatric surgery. This unit explains what tirzepatide is, why it matters, and how dual agonism works at a high level.

what this course covers

01 Introduction to Tirzepatide free 02 Molecular Architecture paid 03 The GIP Pathway paid 04 The GLP-1 Pathway paid 05 Dual Agonism in Action paid 06 Clinical Evidence: Diabetes paid 07 Clinical Evidence: Weight Loss paid 08 Beyond Obesity paid 09 Safety & Monitoring paid 10 Dosing & Administration paid 11 Regulatory & Market Landscape paid 12 Final Exam & Certification paid

What Is Tirzepatide

Tirzepatide is a 39-amino-acid synthetic peptide engineered to activate two incretin hormone receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1).

Unlike earlier drugs that targeted only GLP-1, tirzepatide was designed from scratch as a dual agonist. Its peptide backbone is based on the native GIP sequence, with modifications that give it meaningful GLP-1 receptor activity as well. A C20 fatty diacid side chain anchors it to serum albumin, extending its half-life to roughly 5 days and enabling once-weekly dosing.

The result is a single injection that engages two complementary metabolic pathways: GIP signaling for fat metabolism, beta-cell function, and energy balance, plus GLP-1 signaling for appetite suppression, gastric emptying, and glucose-dependent insulin secretion.

important context: this course covers tirzepatide for educational purposes only. tirzepatide is an approved prescription medication. all clinical data discussed comes from published trials and FDA review documents. consult a healthcare professional for any medical decisions.

Why Tirzepatide Matters

Tirzepatide did not just add a percentage point to weight-loss benchmarks. It rewrote the assumptions about what a drug could achieve.

for diabetes: in the SURPASS trial program, tirzepatide produced HbA1c reductions of up to 2.6 percentage points, outperforming semaglutide 1mg head-to-head in SURPASS-2. many participants reached an HbA1c below 5.7% -- below the threshold for prediabetes.

for obesity: SURMOUNT-1 showed mean weight loss of 22.5% at the highest dose (15mg) over 72 weeks. more than a third of participants on the top dose lost 25% or more of their body weight. these numbers were in the range previously seen only with gastric sleeve surgery.

for the field: tirzepatide proved that adding a second receptor target to GLP-1 agonism could meaningfully increase efficacy. that insight opened the door to triple agonists like retatrutide and a wave of next-generation multi-receptor drugs now in development.

22.5%
max weight loss (SURMOUNT-1)
2.6pp
HbA1c reduction (SURPASS)
2022
FDA approval (Mounjaro)
2 receptors
GIP + GLP-1 dual agonism

How Dual Agonism Works

A high-level look at the two-receptor mechanism before diving deeper in later units.

interactive dual agonism overview

each receptor contributes something different to the overall metabolic effect:

GIP receptor: glucose-dependent insulinotropic polypeptide receptor. enhances beta-cell insulin secretion, improves fat metabolism and lipid storage in adipose tissue, and may contribute to central appetite regulation. tirzepatide has high potency at GIPR -- roughly 5x the activity of native GIP.

GLP-1 receptor: glucagon-like peptide-1 receptor. suppresses appetite via hypothalamic signaling, delays gastric emptying, stimulates glucose-dependent insulin secretion, and inhibits glucagon release. tirzepatide activates GLP-1R with lower relative potency compared to selective GLP-1 agonists like semaglutide, but the combined dual signaling produces greater overall weight loss.

key terms

definitions for the technical words that show up across this course. tap to expand.

T tirzepatide peptide
A 39-amino-acid synthetic peptide developed by Lilly, sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Once-weekly injection. The first dual GIP/GLP-1 receptor agonist to reach the market.
D dual agonist drug class
A single drug that activates two receptors at once. Tirzepatide pairs GIP and GLP-1, distinguishing it from single-target drugs like semaglutide and from triple agonists like retatrutide.
G GIP peptide
Glucose-dependent insulinotropic polypeptide -- a gut hormone released after eating. It amplifies the insulin response to a meal and supports fat metabolism in adipose tissue. Tirzepatide is unusually potent at the GIP receptor (about 5x native GIP).
G GLP-1 peptide
Glucagon-like peptide-1 -- a gut hormone that boosts insulin, slows gastric emptying, and reduces appetite via the brain. It is the same receptor pathway used by semaglutide. Tirzepatide adds GIP on top of this baseline.
G GIP receptor receptor
A GPCR found on pancreatic beta cells, fat tissue, and parts of the brain. Activating it boosts insulin release after meals, regulates fat storage, and may help curb appetite. It is the receptor that distinguishes tirzepatide from pure GLP-1 drugs.
G GLP-1 receptor receptor
The receptor that mediates GLP-1's appetite, gastric, and insulin effects. Tirzepatide binds it with lower relative potency than semaglutide, but the combined dual signaling produces greater overall weight loss.
A agonist pharmacology
A molecule that binds a receptor and turns it on. Tirzepatide is described as a "dual agonist" because it activates both GIP and GLP-1 receptors rather than blocking them.
B biased agonism pharmacology
When an agonist preferentially activates some downstream signaling paths over others through the same receptor. Tirzepatide shows biased dual-agonism, with a deliberate ratio of GIP-to-GLP-1 effect that the molecule's design tunes for the desired metabolic profile.
C C20 fatty diacid molecule
A 20-carbon fatty diacid attached to the peptide. It grabs onto serum albumin in the bloodstream, which hides the molecule from rapid kidney clearance and stretches the half-life to about 5 days -- enough for once-weekly dosing.
S SURPASS trial design
Tirzepatide's phase 3 trial program for type 2 diabetes. SURPASS-2 was the head-to-head against semaglutide where tirzepatide produced larger HbA1c and weight reductions, which is the basis for many "more effective than Ozempic" headlines.
S SURMOUNT trial design
Tirzepatide's phase 3 trial program for obesity. SURMOUNT-1 produced about 22.5% body-weight loss at the highest dose, SURMOUNT-4 covered what happens after discontinuation, and SURMOUNT-OSA supported the first FDA approval of an obesity drug for sleep apnea.
M Mounjaro / Zepbound drug class
The two brand names for tirzepatide. Mounjaro is the type 2 diabetes label (FDA-approved 2022). Zepbound is the chronic weight management label (FDA-approved 2023). Same molecule, different indications.

What's Ahead

This is unit 1 of a mastery course with 11 content units plus a final exam, covering every angle of tirzepatide, from molecular engineering to clinical outcomes to the regulatory landscape.

In the units ahead, you'll study the 39-amino-acid sequence and the C20 fatty diacid that give tirzepatide its ~5-day half-life, then break down each receptor pathway -- GIP for beta-cell and adipose biology, GLP-1 for appetite and gastric emptying, and the biased dual-agonism that makes two targets better than one.

You'll then dig into the clinical evidence: the SURPASS program for type 2 diabetes (including the head-to-head beating of semaglutide in SURPASS-2), and the SURMOUNT program for obesity (SURMOUNT-1's 20%+ weight loss, SURMOUNT-4's discontinuation data, and the SURMOUNT-OSA first-ever sleep apnea approval). safety, dosing and reconstitution, the compounding controversy, and the next-gen pipeline (retatrutide, cagrisema) all get their own units.

Every claim traces back to a primary source, and every limit of the evidence is stated explicitly. This course is designed to let you evaluate tirzepatide critically -- not to promote it.

Knowledge Check

Test what you've learned about tirzepatide and the dual agonist concept.

Practice Exercises

Reinforce your understanding with interactive exercises.

Next Unit

Molecular Architecture